These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37261484)

  • 1. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
    Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.
    Kumar V; Parate S; Danishuddin ; Zeb A; Singh P; Lee G; Jung TS; Lee KW; Ha MW
    Front Cell Infect Microbiol; 2022; 12():909111. PubMed ID: 35846777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
    Kaur M; Silakari O
    J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of promising B lymphocyte kinase inhibitors using structure-guided virtual screening.
    Yang S; Wahab S; Almoyad MAA; Chen Y; Kalam N; Khalid M
    J Biomol Struct Dyn; 2024 Aug; 42(13):7054-7064. PubMed ID: 37688373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
    Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
    Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.
    Kaur M; Kumari A; Bahia MS; Silakari O
    J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new Syk inhibitors through structure-based virtual screening.
    Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of highly selective spleen tyrosine kinase inhibitors.
    Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
    J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syk protein inhibitors treatment for the allergic symptoms associated with hyper immunoglobulin E syndromes: A focused on a computational approach.
    Mansouri M; ElHaddoumi G; Kandoussi I; Belyamani L; Ibrahimi A; El Hafidi N
    Int J Immunopathol Pharmacol; 2024; 38():3946320241282030. PubMed ID: 39241232
    [No Abstract]   [Full Text] [Related]  

  • 14. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases.
    Tang S; Yu Q; Ding C
    Expert Opin Investig Drugs; 2022 Mar; 31(3):291-303. PubMed ID: 35130124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening.
    Villoutreix BO; Laconde G; Lagorce D; Martineau P; Miteva MA; Dariavach P
    PLoS One; 2011; 6(6):e21117. PubMed ID: 21701581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
    Kaur M; Silakari O
    SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Alshehri SA; Wahab S; Almoyad MAA
    J Biomol Struct Dyn; 2024 Nov; 42(18):9463-9474. PubMed ID: 37643015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel
    Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based identification of potential inhibitors of ribosomal protein S6 kinase 1, targeting cancer therapy: a combined docking and molecular dynamics simulations approach.
    Alam A; Khan MS; Mathur Y; Sulaimani MN; Farooqui N; Ahmad SF; Nadeem A; Yadav DK; Mohammad T
    J Biomol Struct Dyn; 2024 Jul; 42(11):5758-5769. PubMed ID: 37365756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.